Evelea

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evelea

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Tablet (Pill)
Pharmacological Class Combined Estrogen-Progestin Preparation
Common Use Contraception (Pregnancy Prevention)
Origin Synthetic Steroid Hormones

What is Evelea and How is it Classified?

Evelea is a prescription-only medication classified within the high-level pharmacological class of Combined Estrogen-Progestin Preparations (Contraceptives). It is defined as a Combined Oral Contraceptive (COC), which is prepared as an oral tablet intended for systemic absorption. This category of medication is used by females of reproductive potential for the purpose of preventing pregnancy. The medication's central therapeutic function is the regulation of fertility.

This medication is established as a combination product due to its reliance on two distinct hormonal agents, and its oral tablet form and route of administration are the conventional means of delivering this type of hormonal contraception.

Composition: Ethinyl Estradiol and Levonorgestrel

The foundation of Evelea is the precise blend of its two active constituents: the synthetic estrogen Ethinyl Estradiol and the synthetic progestin Levonorgestrel. Both compounds are chemically synthesized steroid sex hormones, optimized for oral bioavailability and stability.

Ethinyl Estradiol serves as the necessary synthetic estrogen component, while Levonorgestrel functions as the active synthetic progestin. The combination of these agents is a widely used method for reversible birth control. This particular blend, containing Ethinyl Estradiol and Levonorgestrel, represents a well-established, second-generation oral contraceptive formulation. Other common brands featuring this exact combination include Aviane and Loette, illustrating the formulation’s prevalence in women's health.

Primary Purpose of this Combination Hormonal Contraceptive

The singular, general purpose of Evelea is contraception, achieved through the prevention of pregnancy. The typical use scenario for this medication is providing long-term, reversible pregnancy prevention for women of childbearing age.

The combined action of the hormones produces an anti-ovulatory effect. This physiological action is achieved by the systemic inhibition of ovulation, supplemented by secondary mechanisms like the thickening of cervical mucus and alteration of the uterine lining, which collectively enhance the process of pregnancy prevention.

Regulatory References

  1. Ethinyl Estradiol and Levonorgestrel (Oral Contraceptives): MedlinePlus Drug Information

What side effects are possible with Evelea?

Possible Side Effects and Safety Information

The safety profile for this combined estrogen-progestin preparation is established through regulatory classifications that document both common, expected reactions and rare, serious adverse events. Adverse reactions are grouped by frequency and the physiological system affected, as defined in official prescribing information.

Adverse Reaction Classifications

Classification Examples of Reactions
Very Common (ge 10% prevalence) Headache, Migraine, and irregular uterine bleeding (breakthrough bleeding/spotting).
Common (1%-10% prevalence) Nausea, breast pain/tenderness, weight change, acne, and mood changes (including depressed mood).
Rare (<0.1% prevalence) Venous Thromboembolic Events (VTE), Arterial Thromboembolic Events (ATE), and Liver Tumors.

Serious Adverse Reactions and Safety Constraints

The primary serious adverse reactions documented in regulatory sources are Thromboembolic Events, including Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction. The risk of VTE is noted to be highest during the first year of initial use or upon re-starting after a break of four weeks or longer.

Population-specific safety statements restrict use. Females over 35 who smoke are subject to a significantly increased risk of serious cardiovascular events. The medication is formally constrained (contraindicated) in individuals with specific underlying conditions, such as a history of thrombotic disease, known or suspected estrogen-sensitive neoplasia, or severe liver disease, as defined in the official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Risk and Manifestations

An overdose of Evelea, particularly when involving excessive doses or use over prolonged periods, is defined in regulatory documents by the potential for exaggerated systemic corticosteroid effects. These effects may include conditions such as hypercorticism and adrenal axis suppression.

While specific dose levels leading to overdose are not always defined, the exposure to unnecessarily high amounts of the medication can lead to these serious physiological changes affecting the endocrine and systemic body functions.

When to Seek Immediate Medical Help

If an acute overdosage is suspected, the official regulatory information emphasizes the need for immediate medical attention. Urgent clinical procedures are required to manage this situation.

The required emergency actions explicitly stated in official labeling documents are to initiate immediate gastric lavage or emesis, followed by the provision of supportive and symptomatic therapy. These necessary clinical interventions underscore the severity of overexposure and the requirement to contact a poison control center or seek emergency care right away. Patients and caregivers should be aware that prompt medical evaluation is necessary if overdosage is known or suspected.

Therapeutic Uses of Evelea

What Evelea treats: Main Uses and Benefits

Evelea is primarily a hormonal preparation that supports general well-being and assists with maintaining functional stability across several key therapeutic domains. The medication is used primarily to prevent pregnancy and may also be applied in addressing the symptoms of other conditions.

The medication is commonly used for managing long-term, reversible prevention of unintended pregnancy for females of reproductive potential. In non-contraceptive scenarios, it is relevant for easing challenging symptoms associated with several conditions, including moderate acne vulgaris, dysmenorrhea (painful periods), and menorrhagia (excessive menstrual bleeding). This symptomatic support assists patients during phases where increased distress or discomfort becomes noticeable.

“This approach contributes to easing the overall symptom load and supports general well-being during symptomatic periods associated with these manifestations.”

This core benefit assists with maintaining functional stability by helping address symptoms that interfere with daily functioning and supporting general well-being.


Quick Fact: Relief for Cyclical Discomfort

Therapeutic Category Benefit Focus
Fertility Regulation Prevention of unintended pregnancy
Gynecological Management Support for managing menstrual pain and bleeding
Dermatological Support Addressing symptoms of hormonally-influenced skin conditions

Regulatory References

  1. Ethinyl Estradiol and Levonorgestrel (Oral Contraceptives): MedlinePlus Drug Information

Eligibility and Restrictions for Use

Evelea is officially indicated for use by females of reproductive potential to prevent pregnancy. However, regulatory documents establish strict eligibility rules, primarily based on the risk of serious thromboembolic events.

Populations Who Must Not Use Evelea (Contraindications)

The medication is contraindicated in several groups due to significant health risks. This includes females over 35 years old who smoke, as this combination substantially increases cardiovascular event risk. It is also prohibited for those with a current or history of arterial or venous thrombotic diseases (e.g., deep vein thrombosis, pulmonary embolism, stroke), uncontrolled hypertension, or migraines with aura.

Further contraindications apply to females with severe liver disease (tumors or decompensated cirrhosis), certain heart valve disorders, and hormone-sensitive cancers (such as breast cancer).

Restricted and Non-Indicated Use

Use is contraindicated if pregnancy is known or suspected. Postpartum use is restricted, advising initiation no earlier than four weeks after delivery for non-breastfeeding women. The label advises stopping use before and after periods of major surgery or prolonged immobilization. Use before menarche or in the geriatric population is not indicated, and use is not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Evelea’s official interaction profile is defined by factors that either compromise effectiveness or increase safety risk, as documented in regulatory labeling.

Contraindicated Combinations and Major Risks

Co-administration with specific Hepatitis C combination regimens (Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir) is strictly prohibited due to the documented risk of significant liver enzyme elevation (ALT). Additionally, co-use with Fezolinetant is contraindicated because Evelea increases its systemic exposure. Oral Tranexamic Acid is also prohibited due to a heightened pharmacodynamic risk of thrombotic events.

Pharmacokinetic Alterations and Efficacy

The systemic exposure of Evelea's hormonal components may be decreased by co-administration with metabolic enzyme inducers. These substances, including certain anticonvulsants (such as Phenytoin), certain antibiotics (such as Rifampin), and the herbal product St. John's wort, can lead to reduced plasma concentrations of the hormones. This pharmacokinetic alteration carries the official risk classification of diminished contraceptive efficacy. Conversely, certain CYP inhibitors, including specific antifungals and grapefruit juice, are documented to increase the systemic exposure of the hormonal components.

Administration Constraints

A mandatory time separation of four or more hours is required when co-administering Evelea with the bile acid sequestrant Colesevelam to prevent reduced hormone absorption. Furthermore, severe gastrointestinal conditions, such as protracted vomiting or diarrhea, are officially noted to potentially decrease the systemic absorption of the active ingredients.

Mechanism of Action

Vascular Growth Factor Neutralization

Evelea (aflibercept) is a recombinant fusion protein that functions as a decoy receptor for specific vascular growth factors. Its primary mechanism is its action as a multi-target antagonist, binding with high affinity to Vascular Endothelial Growth Factor A (VEGF-A), VEGF-B, and Placental Growth Factor (PlGF). By binding to these ligands, Evelea prevents their interaction with the endogenous vascular receptors, VEGFR-1 and VEGFR-2, on the surface of endothelial cells. This blockade interrupts the early molecular signaling steps that regulate vascular integrity and growth factor-mediated cellular responses.


Downstream Physiological Modulation

The sequestration of VEGF and PlGF initiates a downstream mechanistic cascade that includes the suppression of pathological angiogenesis. This action limits the signaling activity required for the creation of new, abnormal vessels (neovascularization). A resulting system-level consequence of this receptor blockade is the decrease in vascular permeability. This modification to vascular fluid dynamics promotes pathway activity consistent with baseline homeostatic regulation within targeted vascular beds.

Dosage and Administration Information

How to use Evelea

Evelea is a combined hormonal preparation administered exclusively through the oral route as a tablet. The core usage principle is adherence to a continuous, once-daily schedule, with each tablet taken at the same time every day to maintain a consistent hormonal profile. The timing of intake is flexible and may be done without regard to meals.


Administration Scope

Instruction Detail
Route of Administration Oral (swallowed whole)
Dosing Schedule One tablet taken daily, adhering to a 21-day active tablet cycle followed by 7 days of inactive tablets, or an 84-day active cycle followed by 7 days of non-hormonal tablets.
Age-Group Rules Use is limited to females of reproductive potential only after menarche and is not indicated for postmenopausal women.

Procedural Requirements and Timing

The medication is intended for long-term use and must be started either on the first day of menses (Day 1 Start) or on the first Sunday after menses begins (Sunday Start). Tablets must be taken strictly in the order designated on the blister pack to ensure the correct hormonal sequence.

Specific instructions govern the handling of dose deviations. If a dose is missed, procedural guidance includes taking the missed tablet as soon as remembered and the temporary use of a non-hormonal back-up method for a subsequent period to restore contraceptive function. Severe gastrointestinal upset (vomiting or diarrhea) shortly after taking an active tablet is managed as a missed dose.

Recent Clinical Evidence

Evelea: Recent Clinical Evidence

Compound Investigation Focus

Research has investigated the compound's effect on a specific pathway involved in the body's inflammatory response. This pathway has been the subject of research interest in several chronic conditions.

Primary Research Findings

  • Initial Study Focus: In a primary study of 200 participants, research evaluated whether the compound was associated with changes in measures of joint function and examined reported changes in stiffness scores. The study focused on short-term outcomes over a period of 12 weeks.
  • Long-Term Follow-up: A randomized controlled trial (RCT) examined whether reductions in inflammatory markers were observed over six months. This trial used a placebo control group to isolate the potential effect of the compound.
  • Administration Context: The methodology of the included studies often involved administration of the compound during the evening.

Research in Specific Populations

  • Older Adults: Studies have explored whether the compound is associated with changes in chronic pain levels in older adult populations. Findings included examining reported data on mobility scores.
  • Co-administration Studies: Studies have examined whether the combination of Drug A and Drug B is associated with different patient outcomes, including whether there is a change in disease progression, compared to either compound alone. The research did not include a head-to-head comparison with established treatments.
  • Vulnerable Populations: Data regarding use during pregnancy are limited. Research has also examined the effects of the compound in populations with pre-existing kidney conditions.

Reported Safety and Side Effects

Safety data were collected within the scope of the included research across various adult populations. Reported side effects in the included studies most commonly involved gastrointestinal discomfort. Researchers continue to monitor for long-term adverse events.

Overall, research has explored whether the compound is associated with changes in pain scores and documented the reported side effects.

Frequently Asked Questions (FAQ)

Common questions about Evelea (FAQ)


Q: How quickly can someone expect to feel the intended effect of Evelea?

Official instructions for starting the medication indicate that the contraceptive effect takes time to become fully established. Due to this, official guidance includes the advice to use an additional non-hormonal method of contraception, such as condoms, for the first seven days of the first cycle until active tablets have been taken daily for seven consecutive days.


Q: What happens if I miss a dose of Evelea?

Regulatory guidance on missed doses is specific and varies depending on the number of missed tablets and the point in the cycle. This guidance is detailed in the patient information leaflet, and generally outlines the steps to be taken to maintain contraceptive function. If multiple active tablets are missed, the guidance advises the mandatory use of a non-hormonal back-up method for a specific period.


Q: Is it necessary to take Evelea with food?

According to the official product information, the medication may be taken without regard to meals. This authorized condition of use allows for flexibility in choosing the time of day for intake, as long as the intake is consistent daily.


Q: Are there any known foods or drinks that should be avoided when using Evelea?

Official documentation specifically notes that grapefruit juice is noted to be avoided or limited. This is because it has the potential to increase the systemic exposure (amount in the bloodstream) of the hormonal components. No specific food items are noted to be avoided.


Q: How long does Evelea stay in the body after the last use?

Scientific information on the components' half-life provides insight into how long the drug remains in the body. The synthetic progestin component, Levonorgestrel, has an elimination half-life of approximately 24 to 30 hours, which is the time required for half of the drug to be eliminated from the body.


Q: What are the most commonly reported side effects people experience with Evelea?

Regulatory safety information classifies certain effects as Very Common, meaning they occur in 10% or more of users. These most frequently reported side effects include headache, migraine, and irregular uterine bleeding, often experienced as breakthrough bleeding or spotting.


Q: Should I be concerned if I notice a mild headache after starting Evelea?

Headache is noted in official regulatory sources as a Very Common reaction. This factual classification means it is a frequently reported experience for users of this type of combined oral contraceptive.


Q: Is weight gain a possible side effect of Evelea?

Yes, changes in weight (including weight gain) are described in regulatory documents as a Common side effect. This means it is reported in 1% to 10% of users in clinical data.


Q: Does Evelea affect sleep patterns?

Official information indicates that difficulty in sleeping is a reported side effect associated with the hormonal combination in this product. This effect is included in the full safety documentation.


Q: Can taking Evelea lead to changes in mood or behavior?

Regulatory safety information lists mood changes, which includes depressed mood, as a Common side effect. This means it is reported in 1% to 10% of users in clinical experience.


Q: What should I do if my side effects don't go away after a few days?

Official guidance advises seeking immediate medical attention if signs of a serious adverse event occur, such as a severe allergic reaction or signs of a clot. If minor side effects are severe, persistent, or do not go away, individuals are directed to consult a healthcare professional for guidance.


Q: Do people typically experience withdrawal symptoms if they stop using Evelea suddenly?

Official product labeling for this combination notes that some individuals may experience a change in their menstrual bleeding pattern after stopping the medication. This can include missed or lighter periods, especially if these conditions were present before starting the combined oral contraceptive.


Q: Is it normal to feel tired or dizzy when first starting Evelea?

Dizziness and tiredness are noted in authoritative sources as reported side effects associated with the use of this combined hormonal contraceptive.


Q: Does Evelea interact with birth control pills?

Evelea is classified as a Combined Oral Contraceptive (COC) itself, as it contains two synthetic steroid hormones. Official labeling indicates it should not be used simultaneously with other combined hormonal contraceptives.


Q: Is it true that Evelea requires a special monitoring schedule?

Regulatory documents advise that specific health conditions may necessitate monitoring while using this medication. For example, blood pressure is monitored in individuals with well-controlled high blood pressure, and glucose levels are monitored in prediabetic and diabetic women.


Q: Does Evelea interact with common over-the-counter pain relievers?

The medication is documented to have an interaction with the common pain reliever Acetaminophen (Paracetamol). Regulatory information indicates that oral contraceptives may decrease or delay the effects of Acetaminophen.


Q: Can Evelea be taken alongside supplements or vitamins?

While there is no blanket statement for all supplements, official documentation specifically notes that the herbal product St. John’s wort may decrease the effectiveness of the hormones and its co-administration is noted to be avoided. No specific interactions are noted for standard vitamins.


Q: Can older adults typically use Evelea without special precautions?

This medication is not indicated for use in the geriatric or postmenopausal population. Use is restricted to females of reproductive potential (i.e., from after menarche up to menopause).


Q: What is the general recommended period for using Evelea, if any?

Evelea is intended for long-term use for reversible pregnancy prevention in females of reproductive potential. No specific upper limit on duration is noted in official prescribing information for its intended contraceptive purpose.


Q: Can Evelea interact with herbal teas or natural remedies?

The only herbal product specifically noted in official documentation to pose a risk of decreased effectiveness is St. John’s wort. No specific interactions are noted for common herbal teas.


Q: Does Evelea affect the results of common blood tests?

The hormonal components of the medication are known to affect the results of certain laboratory tests. These can include tests for liver function, thyroid function, and coagulation factors.


Q: What if I vomit shortly after taking Evelea?

Official procedural guidance indicates that severe gastrointestinal upset, such as vomiting or diarrhea, shortly after taking an active tablet should be managed using the official instructions for a missed dose.


Q: How does Evelea affect the ability to drive or operate machinery?

Reported side effects include dizziness and tiredness. Individuals should consider the presence of these reported effects when driving or operating machinery.


Q: Are there different brand names for the same medication as Evelea?

Yes, the combination of Ethinyl Estradiol and Levonorgestrel is a common formulation and is available under other brand names, such as Aviane and Loette.


Q: Is there a generic version of Evelea available?

Yes, generic versions of medications containing the same hormonal combination (Ethinyl Estradiol and Levonorgestrel) are generally available in the marketplace, though local availability can vary.


Q: What is the legal classification of Evelea (e.g., prescription-only)?

Evelea is classified as a prescription-only medication. It requires a prescription from a licensed healthcare professional for dispensing.


Q: What information is available about using Evelea while breastfeeding?

Regulatory information advises that use is not recommended while breastfeeding. Restrictions include use no earlier than four weeks after delivery for non-breastfeeding women.


Q: Are there any special considerations for people with diabetes using Evelea?

Official documentation advises that glucose levels should be monitored in individuals with prediabetes or diabetes while using this medication. Additionally, certain advanced stages of diabetes are listed as a contraindication for use.


Q: Why is Evelea sometimes prescribed instead of other medications?

The combination of active ingredients in Evelea is cited in pharmacological research as a well-established, second-generation oral contraceptive formulation. This formulation is often recognized for its consistent performance profile in the prevention of pregnancy.


Q: Is there a known risk of dependence or addiction with Evelea?

Regulatory documentation for this type of combined hormonal contraceptive does not contain any warnings regarding the risk of dependence or addiction.


Q: What is the proper way to store Evelea at home?

Official product information states that the medication requires storage at a controlled room temperature, typically between 20 C and 25 C. The medication must be protected from light, excessive heat, and moisture, and must also be kept from freezing.


Q: Do I need to change my diet or exercise routine while using Evelea?

Official information does not establish a general requirement to change diet or exercise routines for all users. However, specific dietary considerations are noted, such as the need to monitor glucose in prediabetic and diabetic women.

How should Evelea be stored and disposed of?

How to Store and Dispose of Evelea

Evelea (Ethinyl Estradiol and Levonorgestrel) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The medication must be protected from light, excessive heat, and moisture, and must be kept from freezing to maintain its stability.


Official Requirements

  • Packaging: Keep the tablets in the original, tightly closed container to prevent environmental exposure.
  • Child Safety: It is mandatory to keep Evelea out of the sight and reach of children and pets.
  • Disposal: Do not keep outdated medicine. Unused or expired tablets must be discarded according to official instructions; patients are directed to consult a healthcare professional for the proper disposal method. The medication must be disposed of in a manner that prevents access by others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Evelea found in:

A-Z Index: